F-star Therapeutics Operating Income

As of the most recent data (September 2022), FSTX shows a operating income of $-37M. That compares with $-44M in the prior-year period — up 16.7% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, FSTX's operating income is now $-37M (was $-44M) — a 16.7% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether F-star Therapeutics is outperforming or lagging.

Tracking FSTX's operating income over time shows whether F-star Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $-37M That compares with $-44M in the prior-year period — up 16.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this operating income page, Stockcircle has F-star Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $-37M) with ownership activity and broader fundamentals.

F-star Therapeutics's operating income is $-37M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.